Clinical Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T Injection in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Dual CLL1 CD38 targeting CAR T cell therapy Gracell Biotechnology (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
Most Recent Events
- 26 Feb 2025 Status changed from recruiting to discontinued.
- 06 Nov 2023 New trial record